Corporate Tech Investors

Alopexx

Alopexx is a corporate venture capital group that partners with companies that are a good strategic fit.

Venture Investor Overview

Contact Information

Background Information

Overview

Alopexx Enterprises, LLC was founded in 2011 as an outgrowth of a collaboration that led to the successful development and licensing of an early stage pharmaceutical product. That collaboration began in 2006 when the initial company, Alopexx Pharmaceuticals obtained the rights to develop a fully human monoclonal antibody that can be used for the treatment and prevention of staphylococcal and other serious infections.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

10/1/2014

Transaction History

Our records indicate that Alopexx invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Investor Contacts

Title

Name

Email & Social

Principal

Christine de los Reyes

        

Principal

Deborah Ramsdell

        

Chief Executive Officer

Daniel Vlock

        

Funds

No fund closings have been recorded for this company.

Portfolio Companies

Alopexx has invested in only one tech company, according to our database records. If we are missing a portfolio company, please let us know.

Browse more corporate investors:

Alnylam Pharmaceuticals | Alphabet

Share this article

About Our Corporate Tech Investing Database

This corporate tech investor profile is powered by VentureDeal.com, a leading provider of corporate tech investing transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary